Diagnostic Study for Differentiating Functional From Organic Diseases in Patients With Lower GIT Symptoms
Observational · No treatment assigned · Sites not listed yet · Sohag University
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks.
- Patients with no prior diagnosis of IBD or IBS.
- Patients willing to provide informed consent and comply with study requirements.
Plus 1 more requirement(s). There are also 5 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 100 participants are expected to take part.
- Start date: 2025-06-10 (planned).
- Main results expected around 2025-12-10 (estimate from the record).
- No study sites are listed yet. Check the official record for contact details.
Main thing being measured
- efficacy of myeloperoxidase for differentiating irritable bowel syndrome from inflammatory bowel disease. (baseline)
In the researchers’ words
The study is intended to find a new trusted, cost-effective biomarker for differentiating irritable bowel syndrome from inflammatory bowel disease to decrease the use of unnecessary invasive methods in patients with irritable bowel syndrome
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Irritable Bowel Syndrome (IBS); Inflammatory Bowel Disease (IBD) |
| Lead sponsor | Sohag University |
| Enrollment | 100 (estimated) |
| Start date | 2025-06-10 |
| Primary completion (est.) | 2025-12-10 |
| First posted | 2025-06-11 |
| Last updated | 2025-06-11 |
| Official title | Diagnostic Utility of Myeloperoxidase for Differentiating Irritable Bowel Syndrome From Inflammatory Bowel Disease in Patients With Lower GIT Symptoms |
| ClinicalTrials.gov ID | NCT07016529 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: * Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks. * Patients with no prior diagnosis of IBD or IBS. * Patients willing to provide informed consent and comply with study requirements. * Those without recent use of immunosuppressants or anti-inflammatory medications that could affect biomarker levels Exclusion Criteria: * Patients with a confirmed diagnosis of IBD and currently on treatment. * Those with acute gastroenteritis, infectious colitis, or positive stool cultures for pathogens. * Patients diagnosed with colorectal cancer, celiac disease, or other known organic GI disorders. * Recent antibiotic, NSAID, or corticosteroid use within the past 4 weeks. * Pregnant or lactating women.
Locations (0)
No sites listed yet. The official record has contact information.
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.